VAZQUEZ JA, PENG G, SOBEL JD, STEELE-MOORE L, SCHUMAN P, HOLLOWAY W, NEATON J; TERRY BEIRN COMMUNITY PROGRAMS FOR CLINICAL RESEARCH ON AIDS (CPCRA); Interscience Conference on Antimicrobial Agents and Chemotherapy (41st : 2001 : Chicago, Ill.).
Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 2001 Dec 16-19; 41: abstract no. J-1631.
Wayne State University School of Medicine, Detroit, MI
BACKGROUND: Extensive use of antifungals in HIV (+) patients has been associated with increased azole resistance. The effect of fluconazole (Flz) on the susceptibility of Candida recovered from HIV-infected women was evaluated. METHODS: CPCRA-029, a multicenter, randomized, double-blind placebo controlled trial was conducted from 3/93 - 11/95. 173 women (CD4 counts /= 64 microg/ml). 11 patients assigned Flz and 4 assigned placebo had non-albicans Candida strains isolated (all C. glabrata) that were Flz resistant [p=0.11]. On-treatment analysis of the non-albicans Candida species revealed that 15% (9/60) were recovered while on blinded Flz, 3% (1/33) while on placebo, and 29% (11/38) while on open-label Flz. There was substantial azole-cross resistance among the C. glabrata that were Flz resistant. CONCLUSION: Although the frequency of azole-resistance did not significantly increase following Flz prophylaxis, there was a trend toward more in-vitro azole resistance in C. glabrata in patients assigned Flz. Moreover, the majority of resistant vaginal isolates were recovered after initiation of open-label Flz use.
Publication Types:
Keywords:
- AIDS Vaccines
- Acquired Immunodeficiency Syndrome
- Antifungal Agents
- Azoles
- Candida
- Candidiasis
- Disease Susceptibility
- Female
- Fluconazole
- HIV Infections
- HIV Seropositivity
- Humans
- In Vitro
- Miconazole
- Microbial Sensitivity Tests
Other ID:
UI: 102268964
From Meeting Abstracts